Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7 pseudogene 17 (RPL7P17) is a pseudogene of the RPL7 gene, not a protein-coding or functional gene product[5][8]. It does not encode a functional protein or receptor and is not considered a therapeutic target. The parent gene, RPL7, encodes a component of the 60S large ribosomal subunit involved in protein synthesis, but RPL7P17 itself is a non-functional, processed pseudogene that arose from genomic duplication events and does not have known biological or pathological function[4][8][5]. Key clarifications: - RPL7P17 is not a protein, receptor, enzyme, or any other direct molecular target category; it is a pseudogene[5][8]. - There is no evidence in the literature or validated databases that this pseudogene is expressed or translated into a functional product, nor is it implicated in disease biology or targeted by any drugs[5][8]. - The entry is "incorrect" or not targetable if you require a bona fide protein, receptor, or gene product. If your inquiry was instead about the parent gene, use "60S ribosomal protein L7" (RPL7)[1][4]. For the pseudogene RPL7P17, only basic nomenclature and its classification as a pseudogene are accurate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 17 (RPL7P17).